Ask AI
ProCE Banner Activity

FAQs: Expert Perspectives on Evolving Strategies and Equitable Care in mCRPC 

Clinical Thought

In this commentary, experts address questions about the utility of novel emerging treatment options for patients with mCRPC and highlight their thoughts on ways to ensure equitable care for all patients regardless of ethnicity, socioeconomic status, or level of education.

Released: July 09, 2025

Expiration: January 08, 2026

Share

Provided by

Provided by Clinical Care Options, LLC in partnership with ZERO Prostate Cancer

ProCE Banner

Supporters

Supported by educational grants from Novartis Pharmaceuticals Corporation and Pfizer, Inc.

Novartis Pharmaceuticals Corporation

Pfizer, Inc.

Partners

ZERO Prostate Cancer

ProCE Banner

Disclosure

Primary Author

Alicia K. Morgans, MD, MPH, FASCO: consultant/advisor/speaker: Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Curium, Exact Science, Exelixis, Janssen, Lantheus, Merck, Novartis, Pfizer, Sumitomo, Telix, Tolmar.

Charles J. Ryan, MD: consultant/advisor/speaker: Bayer, Oric, Pfizer.

Neal D. Shore, MD, FACS: consultant/advisor/speaker: Accord, Alessa, Amgen, Antev, Arquer, Asieris, Astellas, AstraZeneca, Aura Biosciences, Bayer, BioProtect, Bristol Myers Squibb, CG Oncology, Clarity, Dendreon, Exact Imaging, Ferring, Fize Medical, Glytherix, Invitae, Janssen, Lantheus, Lilly, MDXHealth, Merck, Minomic, Myriad, Novartis, Photocure, Pfizer, Preview, Promaxo, Propella, Protara, Sanofi Genzyme, Siemens, Specialty Networks, Sumitomo, Telix, Tolmar, Tutelix, Urogen.